[{"edinetCode":"E31382","endDate":"2017\/1\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":37.0,"averageTemporaryStaff":0.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":26072834.0,"sharesOwendPercent":0.5779,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":101.52,"equityRatio":0.728,"cashAndCashEquivalents":4876574000.0,"assets":6292414000.0,"currentAssets":6124564000.0,"fixedAsset":167849000.0,"tangibleFixedAssets":148371000.0,"intangibleFixedAssets":7701000.0,"investmentAndOtherAssets":11776000.0,"liabilities":1697415000.0,"currentLiabilities":547395000.0,"shorTermDept":100000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":49980000.0,"fixedLiabilities":1150020000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1150020000.0,"netAsset":4594998000.0,"capitalStock":4601091000.0,"capital":3852012000.0,"capitalSurplus":7563454000.0,"accumulatedEarnings":-6814228000.0,"treasuryStock":-146000.0,"valuationAndConversionAdjustments":-21642000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1932229000.0,"nonOperatingIncome":8810000.0,"nonOperatingExpenses":242799000.0,"interestExpense":12549000.0,"ordinaryProfit":-2166218000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-2166218000.0,"incomeTaxes":-330922000.0,"netIncome":-1835296000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1835296000.0,"comprehensiveIncome":-1876300000.0,"eps":-40.88,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1796175000.0,"depreciationAndCashflowFromOperatingActivities":26758000.0,"cashFlowFromInvestingActivities":79172000.0,"cashFlowFromFinancialActivities":159283000.0,"changesInCashAndCashEquivalents":-2011228000.0,"列1":"asr","submitDate":"2017\/4\/27","stockCode":4592,"accountingYear":"第４期（自　平成28年２月１日　至　平成29年１月31日）","accountingYearStart":"2016\/2\/1","accountingYearEnd":"2017\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2018\/1\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":32.0,"averageTemporaryStaff":0.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":26892558.0,"sharesOwendPercent":0.5911,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":18.33,"equityRatio":0.161,"cashAndCashEquivalents":4654820000.0,"assets":5193554000.0,"currentAssets":5076825000.0,"fixedAsset":116728000.0,"tangibleFixedAssets":100906000.0,"intangibleFixedAssets":5351000.0,"investmentAndOtherAssets":10470000.0,"liabilities":4340303000.0,"currentLiabilities":2106923000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":66640000.0,"fixedLiabilities":2233380000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2233380000.0,"netAsset":853251000.0,"capitalStock":706851000.0,"capital":3875072000.0,"capitalSurplus":7586514000.0,"accumulatedEarnings":-10754555000.0,"treasuryStock":-180000.0,"valuationAndConversionAdjustments":126936000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-4378381000.0,"nonOperatingIncome":704769000.0,"nonOperatingExpenses":274228000.0,"interestExpense":26143000.0,"ordinaryProfit":-3947840000.0,"extraordinaryGain":8723000.0,"extraordinaryLoss":null,"incomeBeforeTax":-3939117000.0,"incomeTaxes":1210000.0,"netIncome":-3940327000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3940327000.0,"comprehensiveIncome":-3791748000.0,"eps":-86.85,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1906769000.0,"depreciationAndCashflowFromOperatingActivities":53665000.0,"cashFlowFromInvestingActivities":658275000.0,"cashFlowFromFinancialActivities":982416000.0,"changesInCashAndCashEquivalents":-221753000.0,"列1":"asr","submitDate":"2018\/4\/27","stockCode":4592,"accountingYear":"第５期（自　平成29年２月１日　至　平成30年１月31日）","accountingYearStart":"2017\/2\/1","accountingYearEnd":"2018\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2019\/1\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":43.0,"averageTemporaryStaff":0.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":26539796.0,"sharesOwendPercent":0.5336,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":178.42,"equityRatio":0.635,"cashAndCashEquivalents":12453031000.0,"assets":13975975000.0,"currentAssets":13058913000.0,"fixedAsset":917061000.0,"tangibleFixedAssets":74165000.0,"intangibleFixedAssets":2601000.0,"investmentAndOtherAssets":840295000.0,"liabilities":5066854000.0,"currentLiabilities":1066854000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":33380000.0,"fixedLiabilities":4000000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4000000000.0,"netAsset":8909120000.0,"capitalStock":8899393000.0,"capital":9431953000.0,"capitalSurplus":13143396000.0,"accumulatedEarnings":-13675118000.0,"treasuryStock":-837000.0,"valuationAndConversionAdjustments":-25854000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-3733919000.0,"nonOperatingIncome":963932000.0,"nonOperatingExpenses":149936000.0,"interestExpense":33836000.0,"ordinaryProfit":-2919923000.0,"extraordinaryGain":570000.0,"extraordinaryLoss":null,"incomeBeforeTax":-2919353000.0,"incomeTaxes":1210000.0,"netIncome":-2920563000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2920563000.0,"comprehensiveIncome":-3073353000.0,"eps":-60.17,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-3968342000.0,"depreciationAndCashflowFromOperatingActivities":36861000.0,"cashFlowFromInvestingActivities":-1007092000.0,"cashFlowFromFinancialActivities":12719575000.0,"changesInCashAndCashEquivalents":7798211000.0,"列1":"asr","submitDate":"2019\/4\/26","stockCode":4592,"accountingYear":"第６期（自　2018年２月１日　至　2019年１月31日）","accountingYearStart":"2018\/2\/1","accountingYearEnd":"2019\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2019\/4\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.62,"cashAndCashEquivalents":null,"assets":12889409000.0,"currentAssets":11957520000.0,"fixedAsset":931889000.0,"tangibleFixedAssets":61902000.0,"intangibleFixedAssets":1970000.0,"investmentAndOtherAssets":868016000.0,"liabilities":4860595000.0,"currentLiabilities":860595000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":16720000.0,"fixedLiabilities":4000000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4000000000.0,"netAsset":8028814000.0,"capitalStock":8163436000.0,"capital":9432048000.0,"capitalSurplus":13143490000.0,"accumulatedEarnings":-14411266000.0,"treasuryStock":-837000.0,"valuationAndConversionAdjustments":-176463000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1248846000.0,"nonOperatingIncome":536443000.0,"nonOperatingExpenses":14763000.0,"interestExpense":11658000.0,"ordinaryProfit":-727166000.0,"extraordinaryGain":null,"extraordinaryLoss":7522000.0,"incomeBeforeTax":-734688000.0,"incomeTaxes":1458000.0,"netIncome":-736147000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-736147000.0,"comprehensiveIncome":-886756000.0,"eps":-14.8,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/6\/14","stockCode":4592,"accountingYear":null,"accountingYearStart":"2019\/2\/1","accountingYearEnd":"2020\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2019\/7\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":25837037.0,"sharesOwendPercent":0.4994,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.753,"cashAndCashEquivalents":16732829000.0,"assets":18337564000.0,"currentAssets":17584830000.0,"fixedAsset":752734000.0,"tangibleFixedAssets":54629000.0,"intangibleFixedAssets":1234000.0,"investmentAndOtherAssets":696870000.0,"liabilities":4466781000.0,"currentLiabilities":466781000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":4000000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4000000000.0,"netAsset":13870783000.0,"capitalStock":13952807000.0,"capital":8075442000.0,"capitalSurplus":11786884000.0,"accumulatedEarnings":-5908682000.0,"treasuryStock":-837000.0,"valuationAndConversionAdjustments":-139979000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-2385204000.0,"nonOperatingIncome":508825000.0,"nonOperatingExpenses":163270000.0,"interestExpense":24025000.0,"ordinaryProfit":-2039648000.0,"extraordinaryGain":null,"extraordinaryLoss":7442000.0,"incomeBeforeTax":-2047090000.0,"incomeTaxes":1760000.0,"netIncome":-2048851000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2048851000.0,"comprehensiveIncome":-2162977000.0,"eps":-40.62,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-2788974000.0,"depreciationAndCashflowFromOperatingActivities":18724000.0,"cashFlowFromInvestingActivities":-12218000.0,"cashFlowFromFinancialActivities":7036306000.0,"changesInCashAndCashEquivalents":4279797000.0,"列1":"q2r","submitDate":"2019\/9\/13","stockCode":4592,"accountingYear":null,"accountingYearStart":"2019\/2\/1","accountingYearEnd":"2020\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2019\/10\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.733,"cashAndCashEquivalents":null,"assets":17215813000.0,"currentAssets":16409383000.0,"fixedAsset":806429000.0,"tangibleFixedAssets":67155000.0,"intangibleFixedAssets":631000.0,"investmentAndOtherAssets":738643000.0,"liabilities":4522220000.0,"currentLiabilities":522220000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":4000000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":4000000000.0,"netAsset":12693592000.0,"capitalStock":12737803000.0,"capital":8083986000.0,"capitalSurplus":11795428000.0,"accumulatedEarnings":-7140773000.0,"treasuryStock":-837000.0,"valuationAndConversionAdjustments":-124785000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-3628823000.0,"nonOperatingIncome":507128000.0,"nonOperatingExpenses":149788000.0,"interestExpense":35512000.0,"ordinaryProfit":-3271483000.0,"extraordinaryGain":null,"extraordinaryLoss":7382000.0,"incomeBeforeTax":-3278865000.0,"incomeTaxes":2077000.0,"netIncome":-3280943000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3280943000.0,"comprehensiveIncome":-3379874000.0,"eps":-64.47,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/12\/13","stockCode":4592,"accountingYear":null,"accountingYearStart":"2019\/2\/1","accountingYearEnd":"2020\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2020\/1\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":74.0,"averageTemporaryStaff":0.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":24992424.0,"sharesOwendPercent":0.4826,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":209.05,"equityRatio":0.694,"cashAndCashEquivalents":13646073000.0,"assets":15605414000.0,"currentAssets":14626050000.0,"fixedAsset":979364000.0,"tangibleFixedAssets":123943000.0,"intangibleFixedAssets":13650000.0,"investmentAndOtherAssets":841770000.0,"liabilities":4675232000.0,"currentLiabilities":1175232000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":500000000.0,"fixedLiabilities":3500000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3500000000.0,"netAsset":10930182000.0,"capitalStock":10861014000.0,"capital":8083986000.0,"capitalSurplus":11795428000.0,"accumulatedEarnings":-9017546000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":-35296000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-5486070000.0,"nonOperatingIncome":508626000.0,"nonOperatingExpenses":169101000.0,"interestExpense":47363000.0,"ordinaryProfit":-5146544000.0,"extraordinaryGain":null,"extraordinaryLoss":9961000.0,"incomeBeforeTax":-5156506000.0,"incomeTaxes":1209000.0,"netIncome":-5157716000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-5157716000.0,"comprehensiveIncome":-5167158000.0,"eps":-100.91,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-5717292000.0,"depreciationAndCashflowFromOperatingActivities":39638000.0,"cashFlowFromInvestingActivities":-114683000.0,"cashFlowFromFinancialActivities":7022087000.0,"changesInCashAndCashEquivalents":1193042000.0,"列1":"asr","submitDate":"2020\/4\/28","stockCode":4592,"accountingYear":"第７期（自　2019年２月１日　至　2020年１月31日）","accountingYearStart":"2019\/2\/1","accountingYearEnd":"2020\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2020\/4\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.678,"cashAndCashEquivalents":null,"assets":14197674000.0,"currentAssets":13096062000.0,"fixedAsset":1101611000.0,"tangibleFixedAssets":156905000.0,"intangibleFixedAssets":24489000.0,"investmentAndOtherAssets":920216000.0,"liabilities":4449007000.0,"currentLiabilities":949007000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":500000000.0,"fixedLiabilities":3500000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3500000000.0,"netAsset":9748666000.0,"capitalStock":9353947000.0,"capital":8083986000.0,"capitalSurplus":11795428000.0,"accumulatedEarnings":-10524614000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":266356000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1242251000.0,"nonOperatingIncome":7438000.0,"nonOperatingExpenses":270913000.0,"interestExpense":11604000.0,"ordinaryProfit":-1505726000.0,"extraordinaryGain":null,"extraordinaryLoss":47000.0,"incomeBeforeTax":-1505773000.0,"incomeTaxes":1294000.0,"netIncome":-1507067000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1507067000.0,"comprehensiveIncome":-1205415000.0,"eps":-29.1,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/6\/12","stockCode":4592,"accountingYear":null,"accountingYearStart":"2020\/2\/1","accountingYearEnd":"2021\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2020\/7\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":24197589.0,"sharesOwendPercent":0.4672,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.643,"cashAndCashEquivalents":10907649000.0,"assets":13796816000.0,"currentAssets":11728367000.0,"fixedAsset":2068449000.0,"tangibleFixedAssets":177457000.0,"intangibleFixedAssets":33464000.0,"investmentAndOtherAssets":1857528000.0,"liabilities":4776914000.0,"currentLiabilities":2619502000.0,"shorTermDept":500000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1600000000.0,"fixedLiabilities":2157412000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1900000000.0,"netAsset":9019902000.0,"capitalStock":7654617000.0,"capital":5560978000.0,"capitalSurplus":9272421000.0,"accumulatedEarnings":-7177929000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":1210976000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-2570999000.0,"nonOperatingIncome":8252000.0,"nonOperatingExpenses":642916000.0,"interestExpense":23209000.0,"ordinaryProfit":-3205662000.0,"extraordinaryGain":null,"extraordinaryLoss":46000.0,"incomeBeforeTax":-3205709000.0,"incomeTaxes":1596000.0,"netIncome":-3207306000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3207306000.0,"comprehensiveIncome":-1961033000.0,"eps":-61.94,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-2501649000.0,"depreciationAndCashflowFromOperatingActivities":17106000.0,"cashFlowFromInvestingActivities":-88093000.0,"cashFlowFromFinancialActivities":-4048000.0,"changesInCashAndCashEquivalents":-2738424000.0,"列1":"q2r","submitDate":"2020\/9\/14","stockCode":4592,"accountingYear":null,"accountingYearStart":"2020\/2\/1","accountingYearEnd":"2021\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2020\/10\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.606,"cashAndCashEquivalents":null,"assets":13714818000.0,"currentAssets":10133188000.0,"fixedAsset":3581630000.0,"tangibleFixedAssets":159793000.0,"intangibleFixedAssets":36029000.0,"investmentAndOtherAssets":3385807000.0,"liabilities":5220740000.0,"currentLiabilities":2595304000.0,"shorTermDept":500000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1600000000.0,"fixedLiabilities":2625435000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":1900000000.0,"netAsset":8494078000.0,"capitalStock":6020488000.0,"capital":5561072000.0,"capitalSurplus":9272515000.0,"accumulatedEarnings":-8812246000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":2288614000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-4188371000.0,"nonOperatingIncome":8707000.0,"nonOperatingExpenses":660013000.0,"interestExpense":36755000.0,"ordinaryProfit":-4839676000.0,"extraordinaryGain":null,"extraordinaryLoss":46000.0,"incomeBeforeTax":-4839723000.0,"incomeTaxes":1899000.0,"netIncome":-4841623000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-4841623000.0,"comprehensiveIncome":-2517713000.0,"eps":-93.49,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/12\/15","stockCode":4592,"accountingYear":null,"accountingYearStart":"2020\/2\/1","accountingYearEnd":"2021\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2021\/1\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":85.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":24208414.0,"sharesOwendPercent":0.4674,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":157.07,"equityRatio":0.61,"cashAndCashEquivalents":12480165000.0,"assets":13343826000.0,"currentAssets":13131925000.0,"fixedAsset":211900000.0,"tangibleFixedAssets":141784000.0,"intangibleFixedAssets":53650000.0,"investmentAndOtherAssets":16464000.0,"liabilities":4993900000.0,"currentLiabilities":2468900000.0,"shorTermDept":500000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":975000000.0,"fixedLiabilities":2525000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2525000000.0,"netAsset":8349925000.0,"capitalStock":7476235000.0,"capital":5561072000.0,"capitalSurplus":9272515000.0,"accumulatedEarnings":-7356499000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":657644000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-5801740000.0,"nonOperatingIncome":9166000.0,"nonOperatingExpenses":737844000.0,"interestExpense":47170000.0,"ordinaryProfit":-6530418000.0,"extraordinaryGain":3318966000.0,"extraordinaryLoss":46000.0,"incomeBeforeTax":-3211497000.0,"incomeTaxes":174378000.0,"netIncome":-3385875000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3385875000.0,"comprehensiveIncome":-2692935000.0,"eps":-65.38,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-5215683000.0,"depreciationAndCashflowFromOperatingActivities":74455000.0,"cashFlowFromInvestingActivities":4180081000.0,"cashFlowFromFinancialActivities":-56572000.0,"changesInCashAndCashEquivalents":-1165908000.0,"列1":"asr","submitDate":"2021\/4\/28","stockCode":4592,"accountingYear":"第８期（自　2020年２月１日　至　2021年１月31日）","accountingYearStart":"2020\/2\/1","accountingYearEnd":"2021\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2021\/4\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.577,"cashAndCashEquivalents":null,"assets":11520738000.0,"currentAssets":11333010000.0,"fixedAsset":187727000.0,"tangibleFixedAssets":117231000.0,"intangibleFixedAssets":54195000.0,"investmentAndOtherAssets":16300000.0,"liabilities":4620463000.0,"currentLiabilities":2320463000.0,"shorTermDept":500000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":1200000000.0,"fixedLiabilities":2300000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2300000000.0,"netAsset":6900274000.0,"capitalStock":6619375000.0,"capital":5562676000.0,"capitalSurplus":9274118000.0,"accumulatedEarnings":-8216565000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":26361000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1540253000.0,"nonOperatingIncome":698711000.0,"nonOperatingExpenses":13540000.0,"interestExpense":11845000.0,"ordinaryProfit":-855081000.0,"extraordinaryGain":1423000.0,"extraordinaryLoss":null,"incomeBeforeTax":-853657000.0,"incomeTaxes":6408000.0,"netIncome":-860066000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-860066000.0,"comprehensiveIncome":-1491349000.0,"eps":-16.61,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/6\/14","stockCode":4592,"accountingYear":null,"accountingYearStart":"2021\/2\/1","accountingYearEnd":"2022\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2021\/7\/31","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":21457135.0,"sharesOwendPercent":0.4143,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.545,"cashAndCashEquivalents":8794258000.0,"assets":9709380000.0,"currentAssets":9515458000.0,"fixedAsset":193922000.0,"tangibleFixedAssets":108830000.0,"intangibleFixedAssets":53799000.0,"investmentAndOtherAssets":31292000.0,"liabilities":4157329000.0,"currentLiabilities":1857329000.0,"shorTermDept":725000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":675000000.0,"fixedLiabilities":2300000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2300000000.0,"netAsset":5552050000.0,"capitalStock":5345421000.0,"capital":4074182000.0,"capitalSurplus":7785625000.0,"accumulatedEarnings":-6513534000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":-53599000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-3052800000.0,"nonOperatingIncome":933349000.0,"nonOperatingExpenses":27241000.0,"interestExpense":23813000.0,"ordinaryProfit":-2146691000.0,"extraordinaryGain":29487000.0,"extraordinaryLoss":10105000.0,"incomeBeforeTax":-2127309000.0,"incomeTaxes":6711000.0,"netIncome":-2134021000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2134021000.0,"comprehensiveIncome":-2845265000.0,"eps":-41.21,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-3475205000.0,"depreciationAndCashflowFromOperatingActivities":74107000.0,"cashFlowFromInvestingActivities":-27769000.0,"cashFlowFromFinancialActivities":-300385000.0,"changesInCashAndCashEquivalents":-3685907000.0,"列1":"q2r","submitDate":"2021\/9\/14","stockCode":4592,"accountingYear":null,"accountingYearStart":"2021\/2\/1","accountingYearEnd":"2022\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0},{"edinetCode":"E31382","endDate":"2021\/10\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.435,"cashAndCashEquivalents":null,"assets":8285077000.0,"currentAssets":8118698000.0,"fixedAsset":166378000.0,"tangibleFixedAssets":80143000.0,"intangibleFixedAssets":55710000.0,"investmentAndOtherAssets":30524000.0,"liabilities":4387223000.0,"currentLiabilities":2087223000.0,"shorTermDept":950000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":450000000.0,"fixedLiabilities":2300000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2300000000.0,"netAsset":3897853000.0,"capitalStock":4365859000.0,"capital":4075135000.0,"capitalSurplus":7786578000.0,"accumulatedEarnings":-7495000000.0,"treasuryStock":-853000.0,"valuationAndConversionAdjustments":-761421000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":null,"costOfSales":null,"grossProfit":null,"sgaExpenses":null,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-4739819000.0,"nonOperatingIncome":1747411000.0,"nonOperatingExpenses":40292000.0,"interestExpense":35189000.0,"ordinaryProfit":-3032700000.0,"extraordinaryGain":29487000.0,"extraordinaryLoss":10106000.0,"incomeBeforeTax":-3013319000.0,"incomeTaxes":102168000.0,"netIncome":-3115488000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-3115488000.0,"comprehensiveIncome":-4534554000.0,"eps":-60.16,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/12\/15","stockCode":4592,"accountingYear":null,"accountingYearStart":"2021\/2\/1","accountingYearEnd":"2022\/1\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E31382","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":89,"settlementDate":null,"submitterName":"サンバイオ株式会社","submitterNameEnglish":"SanBio Company Limited","submitterNameKana":"サンバイオカブシキガイシャ","location":"中央区明石町８番１号","industory":"医薬品","corporateNumber":6010000000000.0}]